Table of contents
Volume 89, Issue 6
Published online 9 September 2003 (957-1145)
Review |
Clinical |
Molecular and Cellular Pathology |
Genetics and Genomics |
Experimental Therapeutics |
Letters to the Editor
Editorial
Trials and tribulations: obstacles to clinical trial recruitment FREE
N Reed and N Siddiqui
Br J Cancer 89: 957-958; doi:10.1038/sj.bjc.6601233
Review
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature FREE
A-P Meert, B Martin, M Paesmans, T Berghmans, C Mascaux, J-M Verdebout, P Delmotte, J-J Lafitte and J-P Sculier
Br J Cancer 89: 959-965; doi:10.1038/sj.bjc.6601252
Clinical
Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study FREE
O M McNally, E Delaney, R D Petty, M E Cruickshank, A W Hutcheon and D E Parkin
Br J Cancer 89: 966-967; doi:10.1038/sj.bjc.6601071
Intermittent chemotherapy in metastatic androgen-independent prostate cancer FREE
T M Beer, M Garzotto, W D Henner, K M Eilers and E M Wersinger
Br J Cancer 89: 968-970; doi:10.1038/sj.bjc.6601232
Androgen deprivation and cognition in prostate cancer FREE
E Salminen, R Portin, J Korpela, H Backman, L-M Parvinen, H Helenius and M Nurmi
Br J Cancer 89: 971-976; doi:10.1038/sj.bjc.6601235
Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer FREE
A Bottini, A Berruti, M P Brizzi, A Bersiga, D Generali, G Allevi, S Aguggini, G Bolsi, S Bonardi, G Bertoli, P Alquati and L Dogliotti
Br J Cancer 89: 977-982; doi:10.1038/sj.bjc.6601216
Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment FREE
G Hudelist, W J Köstler, J Attems, K Czerwenka, R Müller, M Manavi, G G Steger, E Kubista, C C Zielinski and C F Singer
Br J Cancer 89: 983-991; doi:10.1038/sj.bjc.6601160
Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma FREE
P Comella, A Farris, V Lorusso, S Palmeri, L Maiorino, L De Lucia, F Buzzi, S Mancarella, F De Vita and A Gambardella
Br J Cancer 89: 992-996; doi:10.1038/sj.bjc.6601214
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial FREE
C-H Köhne, R Catane, B Klein, M Ducreux, P Thuss-Patience, N Niederle, M Gips, P Preusser, A Knuth, M Clemens, R Bugat, I Figer, A Shani, B Fages, D Di Betta, C Jacques and H J Wilke
Br J Cancer 89: 997-1001; doi:10.1038/sj.bjc.6601226
Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain FREE
B Ojeda, L M de Sande, A Casado, P Merino and M A Casado
Br J Cancer 89: 1002-1007; doi:10.1038/sj.bjc.6601228
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer FREE
A Fujita, T Ohkubo, H Hoshino, H Takabatake, S Tagaki, K Sekine and S Abe
Br J Cancer 89: 1008-1012; doi:10.1038/sj.bjc.6601230
Supportive care in patients with advanced non-small-cell lung cancer FREE
M Di Maio, F Perrone, C Gallo, R V Iaffaioli, L Manzione, F V Piantedosi, S Cigolari, A Illiano, S Barbera, S F Robbiati, E Piazza, G P Ianniello, L Frontini, E Veltri, F Castiglione, F Rosetti, E De Maio, P Maione and C Gridelli
Br J Cancer 89: 1013-1021; doi:10.1038/sj.bjc.6601236
Performance status score: do patients and their oncologists agree? FREE
S P Blagden, S C Charman, L D Sharples, L R A Magee and D Gilligan
Br J Cancer 89: 1022-1027; doi:10.1038/sj.bjc.6601231
Molecular and Cellular Pathology
Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer FREE
L M Forrest, D C McMillan, C S McArdle, W J Angerson and D J Dunlop
Br J Cancer 89: 1028-1030; doi:10.1038/sj.bjc.6601242
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer FREE
J R Goffin, O Straume, P O Chappuis, J-S Brunet, L R Bégin, N Hamel, N Wong, L A Akslen and W D Foulkes
Br J Cancer 89: 1031-1034; doi:10.1038/sj.bjc.6601195
Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer FREE
C D Archer, M Parton, I E Smith, P A Ellis, J Salter, S Ashley, G Gui, N Sacks, S R Ebbs, W Allum, N Nasiri and M Dowsett
Br J Cancer 89: 1035-1041; doi:10.1038/sj.bjc.6601173
Overexpression of hypoxia-inducible-factor 1
(HIF-1) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage FREE
T Kurokawa, M Miyamoto, K Kato, Y Cho, Y Kawarada, Y Hida, T Shinohara, T Itoh, S Okushiba, S Kondo and H Katoh
Br J Cancer 89: 1042-1047; doi:10.1038/sj.bjc.6601186
Aberrant expression of minichromosome maintenance protein-2 and Ki67 in laryngeal squamous epithelial lesions FREE
P Chatrath, I S Scott, L S Morris, R J Davies, S M Rushbrook, K Bird, S L Vowler, J W Grant, I T Saeed, D Howard, R A Laskey and N Coleman
Br J Cancer 89: 1048-1054; doi:10.1038/sj.bjc.6601234
Cytotoxic T-cell precursor frequencies to HER-2 (369 – 377) in patients with HER-2/neu-positive epithelial tumours FREE
P A Sotiropoulou, S A Perez, E G Iliopoulou, I Missitzis, V Voelter, H Echner, C N Baxevanis and M Papamichail
Br J Cancer 89: 1055-1061; doi:10.1038/sj.bjc.6601244
HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3 FREE
J K Chan, B J Monk, C Brewer, K A Keefe, K Osann, S McMeekin, G S Rose, M Youssef, S P Wilczynski, F L Meyskens and M L Berman
Br J Cancer 89: 1062-1066; doi:10.1038/sj.bjc.6601196
Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients FREE
J Závada, Z Závadová, M Zat'ovi
ová, L Hyr
l and I Kawaciuk
Br J Cancer 89: 1067-1071; doi:10.1038/sj.bjc.6601264
The melanocyte inducing factor MITF is stably expressed in cell lines from human clear cell sarcoma FREE
K K C Li, J Goodall, C R Goding, S-K Liao, C-H Wang, Y-C Lin, H Hiraga, T Nojima, K Nagashima, K-L Schaefer and K A W Lee
Br J Cancer 89: 1072-1078; doi:10.1038/sj.bjc.6601212
Heat shock cognate protein 70 encodes antigenic epitopes recognised by HLA-B4601-restricted cytotoxic T lymphocytes from cancer patients FREE
K Azuma, S Shichijo, H Takedatsu, N Komatsu, H Sawamizu and K Itoh
Br J Cancer 89: 1079-1085; doi:10.1038/sj.bjc.6601203
Genetics and Genomics
A promoter region of the midkine gene that is frequently expressed in human hepatocellular carcinoma can activate a suicide gene as effectively as the -fetoprotein promoter FREE
M Tomizawa, L Yu, A Wada, T Tamaoki, K Kadomatsu, T Muramatsu, S Matsubara, K Watanabe, M Ebara, H Saisho, S Sakiyama and M Tagawa
Br J Cancer 89: 1086-1090; doi:10.1038/sj.bjc.6601246
Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1 FREE
C Gabellini, A Antonelli, P Petrinelli, A Biroccio, L Marcucci, G Nigro, G Russo, G Zupi and R Elli
Br J Cancer 89: 1091-1095; doi:10.1038/sj.bjc.6601213
Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation FREE
H P Marsh, N A Haldar, M Bunce, S E Marshall, K le Monier, S L Winsey, K Christodoulos, D Cranston, K I Welsh and A L Harris
Br J Cancer 89: 1096-1101; doi:10.1038/sj.bjc.6601165
Experimental Therapeutics
n-3 Polyunsaturated fatty acids decrease mucosal/epidermal reactions and enhance antitumour effect of ionising radiation with inhibition of tumour angiogenesis FREE
B Wen, E Deutsch, P Opolon, A Auperin, V Frascogna, E Connault and J Bourhis
Br J Cancer 89: 1102-1107; doi:10.1038/sj.bjc.6601136
Potentiation of tumour apoptosis by human growth hormone via glutathione production and decreased NF-
B activity FREE
C Cherbonnier, O Déas, G Carvalho, G Vassal, A Dürrbach, A Haeffner, B Charpentier, J Bénard and F Hirsch
Br J Cancer 89: 1108-1115; doi:10.1038/sj.bjc.6601223
Increased expression of the ubiquitin – proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-B FREE
A S Whitehouse and M J Tisdale
Br J Cancer 89: 1116-1122; doi:10.1038/sj.bjc.6601132
TNF- increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes FREE
E Katerinaki, G S Evans, P C Lorigan and S MacNeil
Br J Cancer 89: 1123-1129; doi:10.1038/sj.bjc.6601257
An anti-MUC1-antibody–interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells FREE
C Heuser, M Ganser, A Hombach, H Brand, G Denton, F-G Hanisch and H Abken
Br J Cancer 89: 1130-1139; doi:10.1038/sj.bjc.6601267
Letters to the Editor
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group FREE
T Powles, J Shamash, D Berney and R T D Oliver
Br J Cancer 89: 1140-1141; doi:10.1038/sj.bjc.6601176
Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group FREE
C Kollmannsberger and C Bokemeyer
Br J Cancer 89: 1141-1142; doi:10.1038/sj.bjc.6601177
Changes in BMI after treatment of testicular cancer are due to age and hormonal function and not chemotherapy FREE
R A Huddart and A Norman
Br J Cancer 89: 1143-1144; doi:10.1038/sj.bjc.6601178
Reply: Changes in BMI after treatment of testicular cancer are due to age and hormonal function and not chemotherapy FREE
C Nord and S D Fosså
Br J Cancer 89: 1145; doi:10.1038/sj.bjc.6601179
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
